The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $103.95 in the last session, down -0.90% from day before closing price of $104.89. In other words, the price has decreased by -$0.90 from its previous closing price. On the day, 0.8 million shares were traded. BPMC stock price reached its highest trading level at $106.49 during the session, while it also had its lowest trading level at $103.67.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.32. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on November 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $126.
On October 24, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $88.
On May 14, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $140.Stephens initiated its Overweight rating on May 14, 2024, with a $140 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 13 ’25 when Albers Jeffrey W. sold 5,000 shares for $102.28 per share. The transaction valued at 511,400 led to the insider holds 157,557 shares of the business.
Hurley Ariel sold 2,250 shares of BPMC for $225,000 on Jan 13 ’25. The PRINCIPAL ACCOUNTING OFFICER now owns 14,967 shares after completing the transaction at $100.00 per share. On Jan 13 ’25, another insider, Albers Jeffrey W., who serves as the Director of the company, bought 5,000 shares for $102.28 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 6603506688 and an Enterprise Value of 6602040832. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.20 while its Price-to-Book (P/B) ratio in mrq is 21.06. Its current Enterprise Value per Revenue stands at 15.198 whereas that against EBITDA is -25.186.
Stock Price History:
The Beta on a monthly basis for BPMC is 0.59, which has changed by 0.2941394 over the last 52 weeks, in comparison to a change of 0.22677135 over the same period for the S&P500. Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $72.24. The 50-Day Moving Average of the stock is 10.07%, while the 200-Day Moving Average is calculated to be 7.27%.
Shares Statistics:
According to the various share statistics, BPMC traded on average about 709.05K shares per day over the past 3-months and 947540 shares per day over the past 10 days. A total of 63.45M shares are outstanding, with a floating share count of 62.27M. Insiders hold about 1.98% of the company’s shares, while institutions hold 103.38% stake in the company. Shares short for BPMC as of 1735603200 were 5098897 with a Short Ratio of 7.19, compared to 1732838400 on 4185313. Therefore, it implies a Short% of Shares Outstanding of 5098897 and a Short% of Float of 9.04.
